Clinical Evaluation of the Treatment of Spider Angioma

The purpose of this study is to evaluate the safety and efficacy of the 532 nm KTP laser within the Cutera Excel V system for the treatment of spider angiomas.

Inclusion criteria

• Males or females, 5 to 65 years of age (inclusive).
• Fitzpatrick Skin Types I-IV
• Subject must be able to read, understand and sign the Informed Consent Form.
• If subject is a minor (<18 years old in Illinois), Assent must be obtained from the subject and a Parental Consent Form must be signed by the parents or legal guardian.
• Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
• Willing to have limited sun exposure for the duration of the study, including the follow-up period.
• Willingness to have digital photographs taken of their spider angioma(s) and agree to use of photographs for presentation, educational or marketing purposes
• Agree not to undergo any other procedure for the treatment of spider angioma during the study.

Exclusion criteria

• Pregnant.
• History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
• Having a known anti-coagulative condition or taking anticoagulation medications, including aspirin.
• History of seizure disorders due to light.
• Systemic use of isotretinoin (Accutane®) within 6 months of study participation.
• Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
• Participation in a study of another device or drug within 3 months prior to enrollment or during the study.
• In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systemic therapy that could interfere with this research study.